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A cohort study was undertaken to describe outcomes from breast cancer in women who were aged 54 years or younger when they
were first invited for NHS breast screening. The analysis included 5125 women invited for multiple rounds of breast screening by the
Wigan screening programme and 10750 women invited by the Manchester programme. The main outcome measures were rates of
advanced disease and mortality from breast cancer. In Wigan 4028 (78.6%) and in Manchester 5485 (51.0%) women accepted all of
their invitations for screening. The incidence of invasive cancer was higher in Wigan than in Manchester (24.78 vs 21.11 per 10000
person-years; w
2¼2.11, 1df, P¼0.15), but the rate of advanced disease was significantly lower (2.49 vs 4.73 per 10000 person-years;
w
2¼4.36, 1df, P¼0.04). Mortality was lower in Wigan than in Manchester (2.46 vs 4.31 per 10000 person-years; w
2¼3.25, 1df,
P¼0.07). In the first report of long-term outcomes in women invited for NHS breast screening, we demonstrated that it is possible
to evaluate the impact of screening by comparing programmes with different proportions of regular attenders; a significant difference
was shown in the rate of advanced disease between two programmes with different cancer detection and attendance rates.
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The NHS breast-screening programme was introduced in 1988
after the Swedish two-county trial demonstrated a substantial
reduction in mortality from breast cancer in women who received
repeated invitations for screening (Taba `r et al, 1985). The results
of randomised controlled trials cannot always be replicated outside
the trial setting, and the actual impact of NHS breast screening on
breast cancer mortality needs to be determined. However,
evaluating the national programme is problematic because of
changes over time in treatment and in the underlying incidence of
disease (Prior et al, 1996; Blanks et al, 2000a). Furthermore,
mortality data are not routinely linked to screening histories,
which can result in the misclassification of exposure to screening:
for example, the failure to exclude deaths from cancers diagnosed
before the introduction of screening dilutes the observed effect of
the programme (Blanks et al, 2000a). In this study, we used record
linkage to assemble individual screening histories, and relate these
to the occurrence of advanced disease and death from breast
cancer in a cohort of women who received multiple invitations to
screening. This allowed us to compare outcomes in women
attending two screening programmes with substantially different
attendance rates during the same period.
MATERIALS AND METHODS
The base population comprises 17305 women who were aged 54
years or younger when they were first invited for screening by
either the Manchester screening programme, between 1 January
1989 and the 30 September 1990, or by the Wigan screening
programme, between 1 January 1989 and 30 June 1990. The study
population was confined to women aged 54 years or younger
because only these women had a screening experience comparable
to that of the women who are now being invited to screening for
the first time, and future comparisons between programmes will be
restricted to women in this age range. Not all screening
programmes in the North West region commenced screening in
1988, only the Manchester, Wigan, and Bolton programmes were
able to participate at this time. By including only those
programmes that began screening in 1988, the duration of
follow-up was maximised and the confounding effect of secular
trends in the diagnosis and management of disease were avoided.
However, data from the Bolton programme could not be included
because the method of data storage used initially by this
programme did not allow the assembly of full screening histories.
Women invited for screening during 1988 in Wigan and
Manchester were not included to allow for the solution of any
early problems which are inevitable with new systems.
All primary breast cancers occurring in this population were
identified from records held at the North Western Regional Cancer
Registry. To ensure that only residents of the North Western
Region contributed to the analysis, records of all women invited
for screening were linked with those held by the NHS Central
Register. Excluded from further analysis were 113 women who had
died or left the region before their first scheduled screen, 859 who
had their registration with a general practitioner cancelled during
follow-up because their whereabouts were unknown, 266 for whom
no match was found on the NHS Central Register, and 192 women
in whom breast cancer had been diagnosed before their first
scheduled screen.
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screen to which the woman was invited. Women were withdrawn
from follow-up when they died or left the region; end of follow-up in
the remaining women was 30 June 2000. Women who accepted an
invitation to screening were classified as attenders and those who
declined all invitations, nonattenders; women who declined their
first invitation but attended a subsequent screening round
contributed follow-up time to the nonattenders class until they first
attended screening, after which they contributed follow-up time to
the attenders class. Cancers were categorised according to mode of
detection. In attenders, the categories were: first-screen cancers, if
detected at the first screening round; rescreening cancers, if detected
at a subsequent screening round; interval cancers, if diagnosed in
the interval between screens and the woman had attended her
previous screen, or lapsed attender cancers, if detected in the
interval between screens and the women had failed to attend her
previous screen. A cancer in a woman who had never attended
screening was classified as a nonattender cancer.
Following a review of pathology reports and hospital records,
stage at diagnosis was assigned by one of the authors (AGT) using
the International Union Against Cancer classification of tumours
(UICC, 1987). Women with stage III and stage IV disease, and
those with four or more positive lymph nodes, were categorised as
having advanced disease (Bundred et al, 2000; Miller et al, 2000). A
woman was considered to have died from breast cancer, if this was
recorded as the underlying cause of death in sections 1a, 1b, or 1c
of the death certificate. To examine the impact of any population
differences in the prevalence of advanced disease at the first
screening round, incidence and mortality rates are reported both
before and after the exclusion of women found to have cancer at
this time. To determine the relative contribution of each mode of
detection to the overall incidence, advanced disease, and mortality
rates in each population, incidence and mortality rates are
constructed using the total number of person-years accrued by
all women invited for screening by each programme as the
denominator. Statistical methods suitable for small sample sizes
were used, as appropriate, for significance testing and interval
estimation; all tests were conducted at the 5% two-sided
significance level (Martin and Austin, 1996).
RESULTS
The final study population includes 10750 women invited by the
Manchester programme and 5125 by the Wigan programme. A
total of 9074 (84.4%) women in Manchester and 4724 (92.2%) in
Wigan attended on at least one occasion (95% confidence interval
for difference in proportions, 6.8–8.8%); 5485 (51.0%) women in
Manchester and 4028 (78.6%) in Wigan accepted all screening
invitations (95% confidence interval for difference in proportions,
26.1–29.1%). During follow-up, 223 and 129 invasive cancers were
diagnosed in Manchester and Wigan, respectively; their size, stage,
and nodal status are shown in Table 1. A total of 50 women in
Manchester and 13 in Wigan presented with advanced disease, of
whom 33 (66%) and eight (62%) died during follow-up. Cancer
detection rates were higher in Wigan than in Manchester in the
first three screening rounds, but not in the fourth (Table 2).
Table 1 Pathological classification of invasive breast cancer in Manchester and Wigan
Manchester Wigan
UICC stage Pathological classification
a Number % Number %
Io rI I Tumour size p20mm
Node negative 80 36 51 40
1–3 positive nodes 14 6 15 12
Four or more positive nodes 10 4 3 2
Unknown nodal status 31 14 27 21
Tumour size 21–50mm
Node negative 20 9 12 9
1–3 positive nodes 17 8 5 4
Four or more positive nodes 11 5 3 2
Unknown nodal status 6 3 4 3
Size unknown 5 2 2 2
III or IV 29 13 7 5
Total 223 129
aIn nine (6%) cases in Manchester and nine (10%) cases in Wigan, nodal status is based upon less than four lymph nodes.
Table 2 Attendance and cancer detection rates at the first four screening rounds in Manchester and Wigan
Round Programme
Number
invited
a
Number
attended (%)
Invasive
cancers detected
In situ
cancers detected
Detection
rate per 1000 screens
1 Manchester 10750 7727 (71.9) 21 8 3.8
Wigan 5125 4380 (85.5) 18 6 5.5
2 Manchester 10212 7369 (72.2) 17 10 3.7
Wigan 4936 4255 (86.2) 18 5 5.4
3 Manchester 9741 6931 (71.2) 29 6 5.0
Wigan 4703 4157 (88.4) 20 5 6.0
4 Manchester 8118 5719 (70.4) 39 3 7.3
Wigan 3969 3523 (88.8) 20 1 6.0
aIn total, 288 women in Manchester and 164 in Wigan were invited to five or more screens.
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Manchester (24.78 vs 21.11 per 10000 person-years; w
2¼2.11, 1df,
P¼0.146), but the incidence of advanced disease was significantly
lower (2.49 vs 4.73 per 10000 person-years; w
2¼4.36, 1df,
P¼0.04). The rate of advanced disease in nonattenders was
similar in the two populations (7.48 vs 7.73 per 10000 person-
years; w
2¼0.0035, 1df, P¼0.95) and higher than that in attenders.
Mortality rates were lower in Wigan than in Manchester (2.46 vs
4.31 per 10000 person-years; w
2¼3.25, 1df, P¼0.072) and
remained lower after exclusion from the analysis of women found
to have cancer at the first screening round (2.28 vs 4.23 per 10000
person-years; w
2¼3.70, 1df, P¼0.054) (Table 3).
The mode of presentation of all cancers and of advanced
cancers, and the deaths that followed from them, are reported in
Table 4. In Wigan, fewer women were nonattenders and therefore
the contribution of cancers in nonattenders to the overall
incidence of advanced disease was less than in Manchester.
Furthermore, a greater proportion of women in Wigan attended all
of their screens, so fewer cases of advanced breast occurred in
women who lapsed from attending screening.
DISCUSSION
Rates of advanced disease and mortality from breast cancer were
lower in women invited for screening by the Wigan programme
than by the Manchester programme, although the incidence of
breast cancer was higher in Wigan. The lower mortality rate in
Wigan, if not because of chance, must be because of a more
favourable stage distribution, more effective treatment, or a
combination of both. A more favourable stage distribution is the
most likely explanation, because the rate of advanced disease was
significantly lower in Wigan than in Manchester, and advanced
disease had a poor outcome in both populations. Fewer women in
Wigan had nodal surgery, which might suggest that the rate of
advanced disease was underestimated there. However, the
difference in the frequency of nodal surgery was confined to
women with small screen detected tumours, most of which were
detected at screening, and rarely have multiple positive nodes
(Bundred et al, 2000). Therefore, the impact of differences in nodal
surgery on the rates of advanced disease is likely to have been
small. The rate of advanced disease might also be lower in Wigan
Table 3 Incidence, advanced disease, and mortality rates in all invited women, in nonattenders, and in all invited women without cancer detected at the
first screening round, in Manchester and Wigan
Manchester Wigan
Population Person-years
Number
of events
Rate
per10000 years Person-years
Number
of events
Rate per
10000 years
Risk ratio
(95% CI)
All invited women
Incidence 105649 223 21.11 52050 129 24.78 0.85 (0.69–1.06)
Advanced disease 105649 50 4.73 52050 13 2.49 1.89 (1.05–3.62)
Mortality 106784 46 4.31 52773 13 2.46 1.75 (0.96–3.35)
Nonattenders
Incidence 20696 37 17.87 5349 10 18.69 0.96 (0.49–2.02)
Advanced disease 20696 16 7.73 5349 4 7.48 1.03 (0.36–3.60)
Mortality 20857 15 7.19 5380 6 11.15 0.64 (0.26–1.81)
All invited women excluding
cancers detected at first
screen
Incidence 105649 202 19.12 52050 111 21.33 0.90 (0.71–1.13)
Advanced disease 105649 48 4.54 52050 12 2.31 1.97 (1.07–3.86)
Mortality 106489 45 4.23 52538 12 2.28 1.85 (1.00–3.64)
Table 4 Number and rate per 10000 person-years of follow-up of invasive cancers, advanced cancers, and mortality from breast cancer according to
mode of presentation in all women invited for screening by Manchester and Wigan
Invasive cancer Advanced cancer Mortality
Manchester Wigan Manchester Wigan Manchester Wigan
Mode of presentation n Rate n Rate n Rate n Rate n Rate n Rate
First screen 21 1.99 18 3.46 2 0.19 1 0.19 1 0.09 1 0.19
Rescreening 87
a 8.23 58 11.14 9 0.85 2 0.38 8 0.75 1 0.19
Interval 62 5.87 39 7.49 19 1.80 6 1.15 19 1.78 5 0.95
Lapsed attender 16 1.51 4 0.77 4 0.38 0 0.00 3 0.28 0 0.00
Nonattender 37 3.50 10 1.92 16 1.51 4 0.77 15 1.40 6 1.14
Total 223 21.11 129 24.78 50 4.73 13 2.49 46 4.31 13 2.46
aOne cancer was detected in the fifth round and one cancer was detected by the Bolton screening programme.
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earlier with symptomatic disease. However, the incidence of
advanced disease in nonattenders and the prevalence of advanced
disease at the first screening round were similar in the two
populations. Therefore more effective screening, either as a result
of higher detection rates or greater attendance at screening, is the
most likely explanation for the lower rate of advanced disease in
Wigan. Differences in attendance alone, however, cannot fully
explain the difference in the overall rate of advanced disease
between the two populations. Rescreening and interval cancers
contributed more to the rate of advanced disease in Manchester
than in Wigan, possibly because of the lower detection rates in the
early years of the Manchester programme.
Although the magnitudes of the reduction in the incidence of
advanced disease and mortality from breast cancer are coherent
and consistent with a more effective screening programme in
Wigan, the magnitude of the effect is greater than that which would
have been predicted from the results of trials in which
comparisons are made with a control group that is not invited
for screening. We have no compelling explanation as to why this
should be the case, and can only point out that, although the
difference between the two programmes in the incidence of
advanced disease is significant at the 5% level, the 95% confidence
interval is wide, and is consistent with a relative risk reduction of
as little as 7%.
The NHS breast-screening programme is a national programme
that invites all women in the target age range. Therefore, it is not
possible to evaluate the impact of NHS screening by comparing
outcomes from breast cancer in women invited to screening with
those in a contemporaneous control group of uninvited women of
a similar age. However, this study demonstrates that it is possible
to evaluate individual programmes using a cohort study design
with record linkage. This is the first report of long-term outcomes
from breast cancer in women invited for NHS screening and shows
a significant difference in the rate of advanced disease between two
programmes with different cancer detection and attendance rates.
Cancer detection rates have improved throughout the NHS breast-
screening programme and now commonly exceed those seen in
Wigan during this study, but routinely collected statistics do not
allow us to assess whether the high proportion of regular attenders
observed in Wigan has been replicated elsewhere within the
programme (Blanks et al, 2000b). If this proportion varies between
individual programmes, then comparisons between programmes
with different proportions of regular attenders may provide a
means for evaluating the impact of NHS breast screening. The low
rate of advanced disease observed in the Wigan programme
indicates what can be achieved with high cancer detection rates
and regular attendance at screening.
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